[1] ZHANG T.Reflections on establishing a traceability system for drugs, cosmetics, and medical devices[J]. Journal of North Pharmacy(北方药学), 2020,17(5):179-180. [2] MA XY, MO YN.Reflections on the implementation of electronic drug regulation in China[J]. Chinese Pharmaceutical Affairs(中国药事), 2014, 28(9): 977-980. [3] LIU CX, WEN ZQ, ZHANG YZ, et al.Reflections on the construction of China’s drug traceability system[J]. China Medical Herald(中国医药导报), 2017, 14(32): 128-132. [4] YU TX, TIAN K, ZHOU CY.Research on drug traceability system from the perspective of anti monopoly[J]. Health Economics Research(卫生经济研究), 2017(7): 51-54. [5] NMPA. Basic dataset of drug traceability for marketing authorization holders and manufacturers. Basic dataset of drug traceability for distributors. Basic dataset of drug traceability for medical organizations. Basic dataset of drug traceability for consumer inquiry. Basic technical requirements for drug traceability data exchange[EB/OL]. (2020-03-06)[2023-11-14]. https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20200311085301898.html. [6] NMPA. Identification specification for drug traceability code[EB/OL].(2022-06-23)[2023-11-14]. https://www.nmpa.gov.cn/directory/web/nmpa/images/1656320881524098380.pdf. [7] NMPA. Display specification for consumer query results of drug traceability[EB/OL]. (2022-06-23)[2023-11-14]. https://www.nmpa.gov.cn/directory/web/nmpa/images/1656320886699081995.pdf. [8] DU J, CHEN HJ, YU ZC, et al.Application analysis of information traceability technology in the closed-loop management of the entire lifecycle of clinical trial drugs[J]. Pharmaceutical Care and Research(药学服务与研究), 2022, 22(1):58-61. [9] China Daily. Alibaba Health’s“Code on Trust”Helps Pharmaceutical Companies Achieve Full Traceability of Clinical Trial Drugs[EB/OL]. (2021-04-28)[2023-11-24]. https://cn.chinadaily.com/a/202104/28/WS60891d6ea3101e7ce974ca85.html. [10] YIN W.The legalization path of tourism market regulation - from the perspective of responsive regulation[J]. Social Scientist(社会科学家), 2021(10): 46-51. [11] PERERA C,RANJAN R,WANG L,et al.Big data privacy in the internet of things era[J]. IT Professional, 2015, 17(3): 32-39. [12] CHEN YB, WANG Y.Abandonment and storage of electronic drug supervision codes[J]. China Health(中国卫生), 2016(3): 94-95. [13] ZHANG Y, LI DD.Analysis of drug traceability codes[J]. Chinese Pharmaceutical Affairs(中国药事), 2020, 34(11): 1320-1323. [14] ZHANG Y, LI DD.Reflections on the construction of China’s drug traceability system[J]. Chinese Pharmaceutical Affairs(中国药事), 2020, 34(7): 754-758. [15] LIU H, CHAI FY, SONG GS, et al.On the construction of a drug information traceability system related to the newly revised“Drug Management Law”and“Vaccine Management Law”[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2021(5): 98-107. [16] Analysis of the current situation and anti counterfeiting effects of foreign drug tracking and traceability systems[J]. China Anti-Counterfeiting Report(中国防伪报道), 2017(4): 39-42. [17] HUANG WW, HUA J.The enlightenment of foreign drug traceability systems on China[J]. Chinese Pharmaceutical Affairs(中国药事), 2016, 30(12): 1232-1236. [18] FDA. National Drug Code[EB/OL]. (2020-11-12)[2023-11-24].http://en.wikipedia.org/wiki/National_Drug_Code. [19] FDA. Global Trade Item Number[EB/OL]. (2021-10-06)[2023-11-24].http://en.wikipedia.org/wiki/Global_Trade_Item_Number. [20] Dirk Rodgers.Does the DSCSA Have a“Spirit”[EB/OL].(2021-01-15)[2023-11-24].https://www.rxtrace.com/2018/09/does-the-dscsa-have-a-spirit.html/. [21] FENG XC, YANG LY, YANG Y.Research on drug information traceability and safety assurance system in the United States[J] Chinese Pharmaceutical Journal(中国药学杂志), 2019, 54(11): 934-940. [22] EUROPA. AIDE memoire for GMP inspection of manufacturers compliance with commission delegated regulation (EU) 2016/161 for safety features[EB/OL]. (2021-02-16)[2023-11-24]. https://ec.europa.eu/health/sites/health/files/files/falsified medicines/inspection_gmp_aidememoire_en.pdf. [23] ZHOU Q, YU M, HU YM, et al.Introduction and inspiration of EU drug anti-counterfeiting laws and regulations[J]. Chinese Journal of Medicinal Guide(中国医药导刊), 2020, 22(8): 579-583. [24] SHEN JY, LIANG Y.Research on the domestic and international drug traceability system under the framework of drug supply chain security[J]. Chinese Pharmaceutical Affairs(中国药事), 2017, 31(11): 1263-1269. [25] PAN J, XU JF, ZHU LL, et al.Regulatory systems for drug traceability systems in foreign countries and implications for China[J]. Science and Technology Innovation Herald(科技创新导报), 2017, 14(7): 170-171. [26] Health Canada. Drug Identification Number (DIN)[EB/OL]. (2021-11-12)[2023-11-24].https://www.canada.ca/en/health-canada/services/dru-gs-health-products/drug-products/fact-sheets/drug-identification-number.html. [27] SANDEEP DS, RAJ KM, NARAYANAN VA, et al.Regulatory approval process for drugs in Canada - a challenging task[J]. Research Journal of Pharmacy and Technology, 2019, 12(7): 3206-3210. [28] ZHAO Y, LIU WB, ZHAO YF, et al.Practical research and reflection on the application of patient registration research in the science of medical device regulation[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(4): 423-427. [29] HU ZL.Study on the problems and countermeasures in the construction of drug information traceability system in China[J].China Pharmacy(中国药房), 2019, 30(22): 3025-3029. [30] ZHENG C, WU Y, ZHANG L.Research on risk trend analysis methods for EU medical devices after market launch[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2022, 19(1): 79-82. [31] GAO ZH.Public interest: legislative guidance and institutional optimization based on conceptual determination[J]. Jiangxi Social Sciences(江西社会科学), 2021, 41(10): 183-193. [32] YU HS.The reset of drug crime circle in the post era of “Amendment to the Criminal Law(XI)”[J]. Law Science(法学), 2023(2): 62-76. [33] HE RG.Systematic reflection on economic freedom and the legitimacy of economic criminal Law[J]. Law Review(法学评论), 2014(6): 60. |